急性心力衰竭的结合性利尿疗法:系统性审查和元分析
Francesco Fioretti1,2, Angelica Praderio2, Savina Nodari2
1Baylor Scott & White Research Institute, Dallas, TX, USA.
European journal of heart failure
|December 10, 2025
概括
结合性利尿剂策略可以改善急性心力衰竭 (AHF) 患者的早期脱血,但不会影响长期预后. -葡萄糖共载体2抑制剂 (SGLT2i) 在减少心力衰竭事件和恶化功能方面表现有前途.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 目前针对急性心力衰竭 (AHF) 的指南建议增加循环利尿剂量,这可能导致利尿剂耐药性和功能恶化.
- 对于新的治疗方法来有效管理AHF的需求至关重要.
- 评估组合利尿剂策略对于改善患者结果至关重要.
研究的目的:
- 在被诊断为AHF的患者中评估各种联合利尿剂策略的疗效和安全性.
- 为了比较不同的利尿剂方案在管理流体过载和功能方面的有效性.
- 确定AHF的最佳治疗策略.
主要方法:
- 一个系统的审查和11个随机对照试验的元分析,涉及7517名患者.
- 对结果的分析包括所有原因的死亡,心力衰竭事件,减肥,利尿效率和尿液输出.
- 评估-葡萄糖共载体2抑制剂 (SGLT2i) 对功能和HF事件的影响.
主要成果:
- 结合性利尿剂策略增强了早期脱血,由增加的体重减轻和利尿剂效率证明,但没有减少全因死亡或心力衰竭事件.
- 在住院期间服用SGLT2抑制剂显著降低了心力衰竭事件和恶化功能风险.
- 虽然联合治疗改善了流体管理,但它没有改变AHF患者的整体预后.
结论:
- 结合性利尿剂策略在实现AHF早期脱血方面是有效的,但不会影响长期预后.
- 在住院期间使用SGLT2抑制剂与改善死亡率和减少心力衰竭事件有关.
- 对包括SGLT2抑制剂在内的新型利尿策略的进一步研究对于AHF管理是有必要的.
相关概念视频
01:22Heart Failure Drugs: Diuretics
763
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
763
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
01:30Heart Failure V: Medical Management
195
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
195
01:22Heart Failure VI: Adjunct Therapies
228
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
228
01:22Heart Failure Drugs: β-Blockers
724
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
724
01:29Heart Failure II: Pathophysiology
658
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658